Biosimilars: Policy Developments and Emerging Competition Issues
12 PM EST
This program will address recent developments relating to the unique challenges that follow-on biologics (also known as biosimilars) present for regulators, policymakers, and drugmakers. While biosimilars are not yet available in the U.S. market, sales have begun in Europe. Among other things, this panel will discuss Europe's experience with biosimilars and the implications that the European experience has for U.S. regulation and sales of biosimilars, expected to begin in 2015.
* Amanda G. Lewis, Federal Trade Commission
* Susan DeSanti, Federal Trade Commission
* Alexander Roediger, MSD (Europe) Inc.
* Maria Salgado, Cornerstone Research
* Darren Tucker, Bingham McCutchen
FREE: Antitrust Section Members, Government, Non-Profit Employees and Students
$25.00: Other Non-Members
Learn about Section Membership or call 800-285-2221 to join with source code: RAT14IP25. Instructions for accessing the live program will be provided in an confirmation email. For this and all upcoming events visit: http://AmBar.orjg/ATEvents.
The ABA is not seeking CLE credit for this program.
Provided all releases are obtained, MP3 recordings of this program will be available to Section members on the Committee Program Audio page.